Employees: 1,850
Size Embecta (EMBC) is a United States Health Care company (Medical Specialties) with a market value of $345M, the 2965th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.09 on 18 Nov 2026.
Performance Over six months the shares gained 99.0%, against -15.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue fell 7.6% over the last twelve months (peer median +7.0%); the operating margin is 26.4% (peer median 7.9%).
Valuation It trades at 3.8× forward earnings against a peer median of 18.2× (cheapest of 12).
Price implies For today's price to make sense, revenue must grow about -20% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 25.4 points above its cost of capital (6.2% WACC).
Short interest Short interest is 10.3% of the free float (30 Oct 2026).
Next results Next results expected around 1 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.02B | $1.08B | $1.12B | $1.12B | $1.13B |
| Revenue growth | — | -4% | 0% | -1% | — |
| Gross profit | $608M | $680M | $729M | $750M | $775M |
| EBITDA | $323M | $380M | $217M | $262M | $410M |
| Net income | $87.5M | $95.4M | $78.3M | $70.4M | $224M |
| Free cash flow | $165M | $182M | $19.9M | $41.2M | $389M |
| Capital expenditure | $9.50M | $9.30M | $15.8M | $26.5M | $24.0M |
| Total debt | $1.50B | $1.45B | $1.63B | $1.66B | $1.65B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EMBC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.1% | -9.8% | 8th highest of 21 |
| 6-month return | +99.0% | -15.3% | 2nd highest of 20 |
| Distance from 52-week high | -58.9% | -42.8% | 5th lowest of 21 |
| Revenue growth (TTM) | -7.6% | +7.0% | 5th lowest of 21 |
| Operating margin | 26.4% | 7.9% | 5th highest of 21 |
| Forward P/E | 3.8× | 18.2× | cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | -19.9% | 15.8% | least demanding of 16 |
| Growth delivered (Del g) | -0.1% | +0.4% | 7th lowest of 16 |
| Hurdle (Req g minus delivered) | -19.8 pp | +6.1 pp | 3rd least demanding of 16 |
| ROIC minus cost of capital | +25.4 pp | +0.6 pp | 3rd highest of 19 |
| EV / EBITDA | 5.0× | 10.2× | 2nd cheapest of 11 |
| Net debt / EBITDA | 4.0× | -2.1× | most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 3.8× | -19.9% | -0.1% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | n/a | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 25.2× | -0.3% | -0.7% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 17.5× | 35.3% | +5.2% |
| BioNote 377740.KS | South Korea | $337M | -14% | +12% | 18% | 14.4× | -15.0% | -28.5% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $336M | -36% | -5% | 2% | n/a | 34.3% | +0.4% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Tauns Laboratories 197A.T | Japan | $327M | -3% | +7% | 29% | 16.7× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $327M | -24% | -10% | 4% | n/a | 15.8% | -4.5% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $326M | -34% | -15% | -10% | 862.0× | 20.0% | -5.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $326M | -27% | +12% | -2% | n/a | n/a | n/a |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| Japan Eyewear 5889.T | Japan | $318M | -5% | +15% | 32% | 10.7× | -9.4% | +20.2% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | n/a | 17.1% | +18.1% |